Lupin, MonoSol Rx ink licensing agreement for pediatric products

WARREN, New Jersey, BALTIMORE and MUMBAI — Lupin on Tuesday announced a new strategic licensing agreement with specialty pharmaceutical company MonoSol Rx. Under the agreement, Lupin would develop multiple pediatric products using Monosol Rx’s PharmFilm drug delivery technology. 

 

PharmFilm allows for precision dosing in the form of taste-masked dissolvable film, which MonoSol Rx says is an alternative to pills, injections and gels for patients with difficulty swallowing pills or tolerating traditional forms of delivery. 

 

"We believe PharmFilm technology holds great promise for pediatric applications — enabling increased compliance and adherence in a difficult to treat population," MonoSol Rx CEO Keith J. Kendall said. "By partnering with Lupin, whose commitment to support and expand within the pediatric and family-focused market matches our own commitment to helping pediatric patients and their families, we are taking a critical step forward in developing valuable and much-needed products."

 

Lupin said the agreement was in line with its focus on expanding into the specialty market, particularly with regard to such pediatric needs as attention deficit/hyperactivity disorder. 

 

“At Lupin, we are motivated by addressing urgent, unmet medical needs - and helping children and their families ensure they are able to access, tolerate and successfully take the medicines they need is a clear part of that mission," Lupin Pharmaceuticals president Paul McGarty said. "Our alliance with MonoSol Rx will enable us to expand our family of pediatric products to help meet the needs of children for a variety of indications. We look forward to working with MonoSol Rx on the development of these products."